Status:
UNKNOWN
Gene Mutation Spectrum of Malignant Hyperthermia in China
Lead Sponsor:
West China Hospital
Conditions:
Malignant Hyperthermia
Eligibility:
All Genders
Brief Summary
In this study, case information and specimens of patients with malignant hyperthermia(MH) will be collected from all over China, and gene fragment analysis, sanger sequencing method and/or high-throug...
Detailed Description
When MH cases or suspected cases occur in China, anesthesiologists can seek help through malignant hyperthermia emergency rescue WeChat group in which experts from all over the country will give thera...
Eligibility Criteria
Inclusion
- Chinese whose malignant hyperthermia susceptibility had been confirmed after a positive clinical manifestation of malignant hyperthermia which defined as their scores of clinical grading scale for malignant hyperthermia are more than 35 and their blood relations.
- Sign informed consent
Exclusion
- Patients who have no adverse anaesthetic event, such as those patients referred with a history of exertional heat illness, exertional or recurrent rhabdomyolysis, or a congenital myopathy.
Key Trial Info
Start Date :
January 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04474860
Start Date
January 15 2019
End Date
January 1 2024
Last Update
November 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041